Short Interest in Otsuka Holdings Co., Ltd. - Unsponsored ADR (OTCMKTS:OTSKY) Increases By 224.1%

Key Points

• Short interest in Otsuka Holdings Co., Ltd. increased by 224.1% in September, rising from 7,900 shares to 25,600 shares.
• Zacks Research upgraded Otsuka’s rating from a "strong sell" to a "hold" on October 13th, 2023.
• The stock currently has a market capitalization of $29.28 billion and a price-to-earnings ratio of 0.18.

Otsuka Holdings Co., Ltd. - Unsponsored ADR (OTCMKTS:OTSKY - Get Free Report) was the recipient of a large increase in short interest in September. As of September 30th, there was short interest totaling 25,600 shares, an increase of 224.1% from the September 15th total of 7,900 shares. Based on an average daily trading volume, of 76,100 shares, the days-to-cover ratio is currently 0.3 days. Based on an average daily trading volume, of 76,100 shares, the days-to-cover ratio is currently 0.3 days.

Analyst Upgrades and Downgrades

Separately, Zacks Research upgraded Otsuka from a "strong sell" rating to a "hold" rating in a research report on Monday, October 13th. One equities research analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold".

Otsuka Stock Performance

Shares of OTSKY stock traded up $0.20 on Friday, hitting $27.26. 58,810 shares of the company's stock traded hands, compared to its average volume of 38,411. The stock has a market capitalization of $29.28 billion and a price-to-earnings ratio of 0.18. The company's fifty day simple moving average is $27.31 and its 200 day simple moving average is $25.18. Otsuka has a one year low of $21.64 and a one year high of $32.41.

About Otsuka

Otsuka Holdings Co, Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. The company develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, digestive system, ophthalmology, and diagnostics, as well as intravenous solutions and medical devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.